ClinicalTrials.gg
CompletedNCT02551991Updated Oct 10, 2022Results posted

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

A Phase 2 interventional study of nal-IRI and 5 fluorouracil in Pancreatic Cancer, sponsored by Ipsen. Completed at 36 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-10.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms — 10 open to participants now, 12 under way, none of them phase 3. irinotecan sucrosofate · Pancreatic Neoplasms.

Enrollment
14th of 23
56 · median 64
Started
2015
the only one that year
Phase 2
13 of 23
6 open now
Registered
4th of 23
by date
Lead sponsor
2 of 23
Ipsen

Among the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, this one is the 14th largest by enrollment, is the only one that started in 2015, is one of 13 in phase 2, and was the 4th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

10 of the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About irinotecan sucrosofate

irinotecan sucrosofate: first FDA approval 2015 (ONIVYDE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic pancreatic adenocarcinoma. This study will assess the following regimen:

  • nal-IRI + 5-fluorouracil (5-FU)/leucovorin (LV) + oxaliplatin

The study will be conducted in two parts:

Part 1, consisting of an initial dose exploration (Part 1A) followed by dose expansion (Part 1B) of the irinotecan liposome injection +5-FU/LV + oxaliplatin regimen and Part 2, consisting of a comparison of irinotecan liposome injection-containing regimen versus nab-paclitaxel plus gemcitabine. The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018 (Version 6.0), before it was initiated, as this comparative part of the study is being undertaken as a stand-alone phase III study D-US-60010-001. This CSR only pertains to the single-arm dose exploration and dose expansion Part 1 results and no further reference is made to the comparative Part 2.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • Pancreatic cancer
  • MM-398
  • Metastatic pancreatic cancer
  • First line pancreatic cancer treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the setting
  • Unresectable, locally advanced or metastatic disease; diagnosed within 6 weeks prior to screening
  • At least one tumor lesion measurable by CT or MRI scan (according to v1.1)
  • performance status of 0 or 1 at screening and within 72 hours prior to first dose if first dose occurs more than 72 hours post-screening
  • Adequate hematological, hepatic, renal and cardiac function
  • Recovered from the effects of any prior surgery or radiotherapy
  • Patient has a performance status (KPS) ≥ 70 at Screening, and within 72 hours prior to date of first dose if first dose occurs more than 72 hours after screening (Part 1B only)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of pancreatic cancer in the setting (or locally advanced setting) with surgery (placement of stent is allowed), radiotherapy, chemotherapy or therapy
  • Prior treatment of pancreatic cancer with chemotherapy in setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities present
  • Uncontrolled Central Nervous System (CNS) metastases
  • gastrointestinal disorder
  • History of any second in the last 3 years. Patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible
  • Presence of any for nal-IRI, irinotecan, 5-FU, leucovorin, oxaliplatin
  • Use of strong or inducers or presence of any other contra indications for irinotecan
  • Pregnant or breast feeding
  • Neuroendocrine or acinar pancreatic carcinoma
  • Serum albumin \< 3 g/dL at screening visit and within 72 hours prior to first dose if first dose occurs more than 72 hours post screening
  • Patients with symptoms and signs of clinically unacceptable deterioration of primary disease at time of screening
  • Previous treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based resulting in disease progression
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    nal-IRI + 5-FU/LV + oxaliplatin

    Drug: nal-IRI · Drug: 5 fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)

    Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT.

    Time frame: From the start of the first study treatment (Cycle 1 Day 1) up to 14 days after the second dose of study treatment, maximum of 42 days

Secondary outcomes

  1. Median Progression Free Survival (PFS)

    The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique.

    Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter (maximum of 278 weeks).

  2. Best Overall Response (BOR)

    The BOR was defined as the best response (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1.

    Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

  3. Overall Response Rate (ORR)

    The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline.

    Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

  4. Disease Control Rate (DCR)

    The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline.

    Time frame: At Week 16

  5. Median Overall Survival (OS)

    The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique.

    Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

  6. Median Duration of Response (DoR)

    The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique.

    Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).

07

Results

Posted Oct 10, 2022
Limitations and caveats
The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018, before it was initiated, as this comparative part of the study is being undertaken as a stand-alone Phase 3 study D-US-60010-001.

Participant flow

This Phase 2 non-comparative, open-label study was conducted in previously untreated metastatic pancreatic cancer participants at 15 investigational sites in Australia, Spain and USA between 19 October 2015 and 15 February 2021.

Participant flow — Overall Study
MilestoneDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1
Started7710725
Completed00000
Not completed7710725
Withdrew: Death578717
Withdrew: Withdrawal by subject10002
Withdrew: Lost to follow-up00100
Withdrew: Sponsor decision10105
Withdrew: Other00001

Outcome measures

PrimaryPart 1A: Number of Participants With Dose-Limiting Toxicities (DLT)

Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT.

Time frame:
From the start of the first study treatment (Cycle 1 Day 1) up to 14 days after the second dose of study treatment, maximum of 42 days
Reported as:
Count of participants · Participants
Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)
ParticipantsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3
Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)2120
SecondaryMedian Progression Free Survival (PFS)

The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique.

Time frame:
RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter (maximum of 278 weeks).
Reported as:
Median · months
Median Progression Free Survival (PFS)
monthsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Median Progression Free Survival (PFS)9.7 (2.96 to NA)32.3 (0.53 to NA)9.2 (0.46 to NA)3.8 (1.22 to 5.78)9.2 (7.59 to 11.20)9.2 (7.59 to 11.96)
SecondaryBest Overall Response (BOR)

The BOR was defined as the best response (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1.

Time frame:
RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Best Overall Response (BOR)26442026
SecondaryOverall Response Rate (ORR)

The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline.

Time frame:
RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Overall Response Rate (ORR)0 (0 to 41.0)42.9 (9.9 to 81.6)30.0 (6.7 to 65.2)14.3 (0.4 to 57.9)32.0 (14.9 to 53.5)34.4 (18.6 to 53.2)
SecondaryDisease Control Rate (DCR)

The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Disease Control Rate (DCR)42.9 (9.9 to 81.6)71.4 (29.0 to 96.3)40.0 (12.2 to 73.8)28.6 (3.7 to 71.0)72.0 (50.6 to 87.9)71.9 (53.3 to 86.3)
SecondaryMedian Overall Survival (OS)

The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique.

Time frame:
RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Reported as:
Median · months
Median Overall Survival (OS)
monthsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Median Overall Survival (OS)12.6 (3.98 to 21.03)12.5 (0.53 to 12.71)16.6 (0.69 to 26.74)5.8 (1.35 to 14.65)12.7 (8.18 to 23.66)12.6 (8.74 to 19.12)
SecondaryMedian Duration of Response (DoR)

The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique.

Time frame:
RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Reported as:
Median · months
Median Duration of Response (DoR)
monthsDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Cohort -1: Pooled
Median Duration of Response (DoR)—28.4 (3.52 to NA)NA (NA to 16.39)—9.4 (2.20 to NA)9.4 (3.52 to NA)

Adverse events

Collected over Treatment-emergent adverse events are reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration or until the start of alternative anticancer therapy, approximately 1008 days. All-Cause Mortality are reported from first participant enrolled to last participant died, approximately 1946 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Exploration: Cohort 15/7 (71.4%)6/7 (85.7%)7/7 (100%)
Dose Exploration: Cohort -17/7 (100%)2/7 (28.6%)7/7 (100%)
Dose Exploration: Cohort -2B8/10 (80%)7/10 (70%)10/10 (100%)
Dose Exploration: Cohort -37/7 (100%)4/7 (57.1%)7/7 (100%)
Dose Expansion: Cohort -117/25 (68%)15/25 (60%)25/25 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1
Abdominal PainGastrointestinal disorders0/70/70/103/71/25
DiarrhoeaGastrointestinal disorders2/71/71/101/71/25
ColitisGastrointestinal disorders0/70/70/102/71/25
VomitingGastrointestinal disorders1/70/72/100/73/25
Small Intestinal ObstructionGastrointestinal disorders0/70/70/101/71/25
EnteritisGastrointestinal disorders1/70/70/100/70/25
Large Intestinal ObstructionGastrointestinal disorders1/70/70/100/70/25
Upper Gastrointestinal HaemorrhageGastrointestinal disorders0/71/70/100/70/25
Febrile NeutropeniaBlood and lymphatic system disorders0/71/70/100/72/25
Anaemia of Malignant DiseaseBlood and lymphatic system disorders0/70/70/101/70/25
Most frequent other events
Showing 10 of 232
Most frequent other events
EventDose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1
NauseaGastrointestinal disorders5/76/79/105/723/25
DiarrhoeaGastrointestinal disorders6/75/76/106/722/25
Decreased appetiteMetabolism and nutrition disorders5/76/74/103/712/25
VomitingGastrointestinal disorders5/74/75/103/714/25
FatigueGeneral disorders5/75/77/105/716/25
DepressionPsychiatric disorders1/75/71/101/72/25
ConstipationGastrointestinal disorders3/74/74/101/713/25
Abdominal painGastrointestinal disorders2/73/73/104/78/25
FlatulenceGastrointestinal disorders0/74/72/101/71/25
HypokalaemiaMetabolism and nutrition disorders4/72/75/103/712/25

Baseline characteristics

Safety population included participants who received at least 1 dose of any study treatment.

Age, Customized
Age, Customized(Participants)Dose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Total
< 65 years44341934
>= 65 years3373622
Sex: Female, Male
Sex: Female, Male(Participants)Dose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Total
Female64221428
Male13851128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Total
White67972150
Black or African American000022
Asian101013
Not Reportable000011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Exploration: Cohort 1Dose Exploration: Cohort -1Dose Exploration: Cohort -2BDose Exploration: Cohort -3Dose Expansion: Cohort -1Total
Hispanic or Latino000044
Not Hispanic or Latino771072152
08

Study locations

36 sites
  • University of South Alabama
    Mobile, Alabama 36604, United States
  • University of South Alabama - Mobile
    Mobile, Alabama 36688, United States
  • Arizona Center for Cancer Care
    Avondale, Arizona 85392, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • UCLA Hematology Oncology - Ventura
    Los Angeles, California 90095, United States
  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Mayo Clinic Cancer Center
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Eastern Maine Medical Cancer Care
    Brewer, Maine 04412, United States
  • Maryland Oncology Hematology
    Silver Spring, Maryland 20904, United States
  • Lahey Hospital & Medical Center
    Burlington, Massachusetts 01805, United States
  • Mayo Clinic Cancer Center - Rochester
    Rochester, Minnesota 55905, United States
  • Oncology Hematology West PC dba Nebraska
    Omaha, Nebraska 68130, United States
  • US Oncology - Comprehensive Cancer Centers of Nevada (CCCN)
    Las Vegas, Nevada 89169, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Oncology/Hematology Care Clinical Trials, LLC
    Cincinnati, Ohio 45230, United States
  • University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Willamette Valley Cancer Institute & Research Center
    Eugene, Oregon 97401, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Medical Group of the Carolinas - Spartanburg Regional Health Services
    Spartanburg, South Carolina 29303, United States
  • Texas Oncology Methodist Dallas Cancer Center
    Dallas, Texas 75203, United States
  • Texas Oncology-Fort Worth 12 Ave
    Fort Worth, Texas 76104, United States
  • Houston Methodist Cancer Center and Institute of Academic Medicine
    Houston, Texas 77030, United States
  • Oncology Consultants - Houston
    Houston, Texas 77030, United States
  • Joe Arrington Cancer Research and Treatment Center - Lubbock
    Lubbock, Texas 79410, United States
  • Texas Oncology, P.A.
    San Antonio, Texas 78217, United States
  • St. John of God Health Care - Subiaco
    Subiaco, Western Australia 6008, Australia
  • Flinders Medical Centre
    Bedford Park, 5042, Australia
  • Box Hill Hospital
    Lilydale, 3140, Australia
  • Hospital General Universitario de Elche
    Elche, Alicante 03203, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC)
    Madrid, 28050, Spain
09

References and documents

Publications

  • Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1550-1563. doi: 10.1002/psp4.12725. Epub 2021 Nov 20. PubMed 34750990 ↗
  • Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4. PubMed 33957442 ↗
  • Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH, Wang X, Tang I, Zheng E, Qiu W, Wainberg ZA, Nel AE, Meng H. Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer. ACS Nano. 2019 Jan 22;13(1):38-53. doi: 10.1021/acsnano.8b06164. Epub 2018 Dec 11. PubMed 30525443 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Feb 2021, 63 months.

Results were first posted in Oct 2022, 1 year 7 months after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 63 months is above that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2015
First posted
Sep 16, 2015
StartActual
Oct 19, 2015
Primary completionActual
Feb 15, 2021
CompletionActual
Feb 15, 2021
Results first posted
Oct 10, 2022
Last update
Oct 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02551991
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 16, 2015
Start date
Oct 19, 2015
Primary completion
Feb 15, 2021
Completion
Feb 15, 2021
Results posted
Oct 10, 2022
Last update
Oct 10, 2022

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan sucrosofate

Start the discussion